This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other seropositive rheumatoid arthritis기타 혈청검사양성 류마티스관절염

Contents and key points
ItemDetails
A. Classification codesICD-10: M05.8 | Special Copayment Reduction: V223 (severe intractable disease, 5 years)
B. SynonymsNo synonyms (other seropositive RA, unclassified seropositive RA)
C. Adult onsetAdult onset: very high - seropositive RA arises almost without exception in adults (mainly 40s-70s).
1. HistorySee main text
2. CausesSee main text
3. GeneticsSee main text
4. General epidemiologySee main text
5. PathophysiologySee main text
6. SymptomsSee main text
7. SignsSee main text
8. ScreeningSee main text
9. DiagnosisSee main text
10. TreatmentSee main text
11. PrognosisSee main text
12. PreventionSee main text
13. ReferencesSee main text

1. History

Rheumatoid arthritis (RA) was named by Garrod in 1858, and the treatment paradigm developed with the introduction of corticosteroids in the 1940s-50s, the establishment of MTX in the 1980s, and the biologic revolution of the 2000s. The joint ACR/EULAR classification criteria were established in 2010.


2. Causes

The cause of RA is the combined action of genetic predisposition such as the HLA-DRB1 shared epitope, PTPN22, and PADI4; environmental factors such as smoking and periodontal infection; and breakdown of immune tolerance to citrullinated autoantigens. TNF-α, IL-1β, IL-6, and IL-17 are the main inflammatory cytokines.


3. Genetics

Carrying the HLA-DRB1 shared epitope (DRB1*04:01, *04:04, *01:01) increases the risk of ACPA-positive RA several-fold. PTPN22 R620W, PADI4 (East Asians), STAT4, CTLA4, and CCR6 are susceptibility genes.

M05.8 (other seropositive RA) is a residual code for classifying seropositive RA other than M05.0 (Felty syndrome), M05.1 (rheumatoid lung disease), M05.2 (vasculitis), and M05.3 (involvement of other organs). The genetic basis is the same as for general seropositive RA.


4. General epidemiology

RA prevalence is 0.5-1% worldwide and about 0.7-1% in Korea. It is 2-3 times more common in women than in men and occurs most often in the 40s-60s. Prognosis has improved markedly since the introduction of biologics and JAK inhibitors.

Seropositive (RF-positive or ACPA-positive) RA accounts for about 60-70% of all RA. M05.8 is seropositive RA other than M05.0-M05.3, and the largest number of seropositive RA patients are classified under this code.


5. Pathophysiology

ACPA/RF formation in the preclinical stage → synovial deposition of immune complexes and complement activation → chronic synovial inflammation (TNF-α, IL-1β, IL-6, IL-17) → RANKL-mediated osteoclast activation (bone erosion) → cartilage loss by MMPs.


6. Symptoms

Main symptoms are polyarticular symmetric arthritis (PIP, MCP, wrist, elbow, knee, ankle), morning stiffness lasting 1 hour or longer, joint swelling, warmth, and tenderness, rheumatoid nodules, fatigue, weight loss, and anemia (anemia of chronic disease).


7. Signs

Blood tests show RF positivity, ACPA positivity, elevated CRP/ESR, and anemia. On radiographs, periarticular osteoporosis, joint space narrowing, and bone erosion are seen as the disease progresses. In the early stage, MRI and joint ultrasound are more sensitive than radiographs.


8. Screening

With a family history of RA, unexplained morning stiffness, or symmetric swelling of small joints: basic tests of RF, ACPA, CRP, and CBC. Early referral to rheumatology in high-risk groups is important for achieving remission.


9. Diagnosis

Apply the 2010 ACR/EULAR classification criteria (total score of 6 or more). Confirm RF or ACPA positivity. Confirm seropositive RA that does not fall under a specific phenotype among M05.0-M05.3. Differentiate from infectious arthritis, reactive arthritis, psoriatic arthritis, SLE, and gout.


10. Treatment

T2T principle: Target clinical remission by DAS28. csDMARD: MTX 15-25 mg/week (first line). bDMARD: anti-TNF (etanercept, adalimumab, etc.), abatacept, rituximab, tocilizumab/sarilumab. tsDMARD: JAK inhibitors (tofacitinib, baricitinib, upadacitinib). Steroids are used at low dose for a short period when inducing remission.


11. Prognosis

Since the introduction of biologics, functional outcomes and mortality in RA have improved markedly. Early aggressive treatment (window of opportunity) is key to determining long-term prognosis. Poor prognostic factors: high ACPA/RF titers, polyarticular involvement, early bone erosion.


12. Prevention

Smoking cessation is the key to preventing ACPA-positive RA. Prevent joint damage with early diagnosis and aggressive DMARD treatment. Tuberculosis screening is essential before starting biologics. Pneumococcal, influenza, and herpes zoster vaccinations are recommended.


13. References

  1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
  2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum. 2010;62(9):2569-2581.
  3. Smolen JS, Landewé RBM, et al. EULAR recommendations for RA management: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
  4. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337.
  5. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183-196.
  6. Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;170(1):ITC1-ITC16.
  7. Singh JA, Saag KG, Bridges SL, et al. 2015 ACR Guideline for Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
  8. Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(1):35-40.
  9. Kim SK, Park SH. Rheumatoid arthritis in Korea. J Korean Med Assoc. 2013;56(2):126-131.
  10. Koh JH, Park EH, Kim K, et al. Incidence and prevalence of RA in South Korea. Rheumatol Int. 2017;37(9):1509-1514.